Overview

Keratinocyte Growth Factor to Prevent Acute GVHD

Status:
Completed

Trial end date:
2003-08-01

Target enrollment:

Participant gender:

Summary

This is a study to determine the safety and efficacy of keratinocyte growth factor (KGF) to prevent acute graft-versus-host disease (GVHD) in patients undergoing allogeneic bone marrow (BM) or peripheral blood progenitor cell (PBPC) transplantation.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

FDA Office of Orphan Products Development

Treatments:

Mitogens